Rotkreuzklinikum Munchen gGmbH
- Address
- lock Available on a paid plan
Hematology and Oncology Research
At Rotkreuzklinikum Munchen gGmbH, clinical studies in hematology and oncology are focused on neoplasms, with particular attention to acute myeloid leukemia. The research is aimed at assessing new treatment approaches and generating early evidence on how well these therapies may work for patients who need alternatives to standard care.
- Evaluation of a new treatment strategy for acute myeloid leukemia
- Exploring the effectiveness of Venetoclax combined with Azacitidine in newly diagnosed patients
- Building first clinical evidence for treatment options in patients not suited to standard induction therapy
The site’s work in this area reflects a strong interest in improving care for blood cancers through practical, patient-focused clinical research.
Otolaryngology and Hearing Protection Studies
Another research focus at this Munich site involves otorhinolaryngologic diseases, especially sensorineural hearing loss. The clinical trial activity is centered on preventing hearing damage and evaluating whether a new therapy may help protect hearing in people exposed to cisplatin-related ototoxicity.
- Studying prevention of sensorineural hearing loss after ototoxic treatment
- Assessing a potential hearing-protection therapy in testicular cancer patients receiving cisplatin
- Measuring whether the intervention can preserve functional hearing outcomes
This research combines cancer care and hearing health, with the goal of reducing treatment-related side effects and improving quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rotkreuzklinikum Munchen gGmbH
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy (VENAZA-5S PILOT TRIAL) | Universitaet Leipzig | Phase II | Not Recruiting | May 2023 | Nov 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acou085 | 1 | Unknown | 2023-11-10 | 2023-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.